Home › Companies › OTLK

Outlook Therapeutics

OTLK Lead: NDA Submitted 3 Biotech Distilled articles ↓

Ophthalmology Protein

Most recent annual filing: 2025-12-19

Pipeline (3 active programs)

LYTENAVA

bevacizumab · ONS-5010

Protein Target: VEGF

Wet Age-Related Macular Degeneration NDA Submitted intravitreal
Diabetic Macular Edema Phase 3 intravitreal
Branch Retinal Vein Occlusion Phase 3 intravitreal

Biotech Distilled coverage (3)

2026-06-02 UPDATE: Outlook Therapeutics (OTLK) — The Clock Starts 🔒 Paid
2026-05-28 UPDATE: Outlook Therapeutics (OTLK) — The Anchor Doubles Down (and Reprices His Warrants) 🔒 Paid
2026-05-27 Outlook Therapeutics (OTLK) – Scientific Deep Dive for ONS-5010/LYTENAVA 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.